Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment

Trial Profile

Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil/lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2016 Interim analysis (n=107) results presented at The International Liver Congress™ 2016
    • 31 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
    • 31 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top